Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses
about
Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondCD40-activated B cells induce anti-tumor immunity in vivo.Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approachEnhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.Pluripotent state induction in mouse embryonic fibroblast using mRNAs of reprogramming factors2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors.Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy.From the RNA world to the clinic.Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts.Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes
P2860
Q26861563-9C5CCC41-B4FF-47E9-92A6-802D704CFED6Q33709425-0FDC5699-173A-4381-8A79-FE5D29CBBE42Q33740816-57FDE45C-31C3-4A7F-928D-624883E3833FQ33786958-A21B6C74-72A4-456A-8FB2-A2759D2D3F3DQ34633278-76B160E2-A008-4AC2-97AF-7772F4FBF13AQ34833754-C5D29AF1-39F4-4AFB-864F-FC1E8B145558Q36987499-A194CC82-B03A-41C4-B915-809EF558C8BDQ37273700-03C5B8F2-FB03-458E-9596-CD56626A8FACQ37440696-B438F260-3746-4A6D-80AD-3E3F0DC10F67Q37564683-C1A03987-4133-4D5F-8543-7671E9806430Q38851919-7E116CD8-C070-431D-BB02-34D656795A1EQ39842438-9F5735EE-D747-4490-B4B4-B96A21C9F5E5Q41761209-880651D2-B564-4E92-BFB5-5D48CB7FECBFQ48319918-7039FD5F-F36F-4DE0-85DF-AEB43DE5C1BEQ51175569-D8636CFF-8382-4C3E-B0B6-4EE180D18416Q58726929-405F7EF7-ED4C-42E3-899F-2314347E9E19
P2860
Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2008
@uk
name
Activated B cells modified by ...... igen-specific T-cell responses
@en
Activated B cells modified by ...... igen-specific T-cell responses
@nl
type
label
Activated B cells modified by ...... igen-specific T-cell responses
@en
Activated B cells modified by ...... igen-specific T-cell responses
@nl
prefLabel
Activated B cells modified by ...... igen-specific T-cell responses
@en
Activated B cells modified by ...... igen-specific T-cell responses
@nl
P2093
P2860
P1433
P1476
Activated B cells modified by ...... igen-specific T-cell responses
@en
P2093
Bruce A Sullenger
Claudia M Dollins
David Boczkowski
Jaewoo Lee
Smita Nair
P2860
P304
P356
10.1111/J.1365-2567.2008.02833.X
P407
P577
2008-10-01T00:00:00Z